Evidence map›Paper›PMID 37249720›Full record

ArticleOdontology2024

Applicability of an active matrix metalloproteinase-8 point-of-care test in an oral and maxillofacial surgery clinic: a pilot study.

Essi Kallio, Tero Puolakkainen, Taina Tervahartiala, Johanna Snäll, Emilia Marttila, Timo Sorsa, Johanna Uittamo

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Odontology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 2 countries.

Essi KallioDepartment of Oral and Maxillofacial Diseases, University of Helsinki and Helsinki University Hospital, Biomedicum 1, Haartmaninkatu 8 (PL 63), 00014, Helsinki, Finland. essi.kallio@helsinki.fi.ORCID http://orcid.org/0009-0008-4451-1749
Tero PuolakkainenDepartment of Oral and Maxillofacial Diseases, University of Helsinki and Helsinki University Hospital, Biomedicum 1, Haartmaninkatu 8 (PL 63), 00014, Helsinki, Finland.
Taina TervahartialaDepartment of Oral and Maxillofacial Diseases, University of Helsinki and Helsinki University Hospital, Biomedicum 1, Haartmaninkatu 8 (PL 63), 00014, Helsinki, Finland.
Johanna SnällDepartment of Oral and Maxillofacial Diseases, University of Helsinki and Helsinki University Hospital, Biomedicum 1, Haartmaninkatu 8 (PL 63), 00014, Helsinki, Finland.
Emilia MarttilaDepartment of Oral and Maxillofacial Diseases, University of Helsinki and Helsinki University Hospital, Biomedicum 1, Haartmaninkatu 8 (PL 63), 00014, Helsinki, Finland.
Timo SorsaDepartment of Oral and Maxillofacial Diseases, University of Helsinki and Helsinki University Hospital, Biomedicum 1, Haartmaninkatu 8 (PL 63), 00014, Helsinki, Finland.
Johanna UittamoDepartment of Oral and Maxillofacial Diseases, University of Helsinki and Helsinki University Hospital, Biomedicum 1, Haartmaninkatu 8 (PL 63), 00014, Helsinki, Finland.
University of Helsinki · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesMatrix metalloproteinases are enzymes that participate in numerous inflammatory responses and have been targeted as biomarkers in numerous pathologic states. The detection of active matrix metalloproteinase-8 (aMMP-8) using a mouthrinse point-of-care test (POCT) has emerged as a diagnostic marker for periodontitis and other systemic inflammatory states. The objective of this pilot study was to assess the applicability of aMMP-8 POCT in an oral and maxillofacial surgery clinic and to evaluate the relationship between aMMP-8 levels and different patient groups. MATERIALS AND

methodsaMMP-8 POCT samples were collected from patients in an oral and maxillofacial surgery clinic during a one-month period. aMMP-8 levels were analyzed using a chairside lateral-flow immunotest and a digital reader. Clinically relevant patient variables were collected and descriptively evaluated. aMMP-8 levels over 20 ng/ml were considered to be elevated.

resultsA total of 115 patients were interviewed of which 112 agreed to the test (97.4%). Elevated aMMP-8 levels were observed in 58 (51.8%) patients. Bone loss was noted in 75 (67.0%) patients. Of these patients, aMMP-8 levels were elevated in 47 (62.7%) patients. Patients at an increased risk of infection had 35.5% higher aMMP-8 values on average compared to patients with no prior illnesses.

conclusionaMMP-8 POCT provides a non-invasive and reliable method for measuring aMMP-8 levels. Future studies are warranted to assess the clinical relevance between elevated aMMP-8 levels and specific patient groups. CLINICAL RELEVANCE: The rapid availability of the test score allows an immediate impact on treatment planning.

Indexed as

Matrix Metalloproteinase 8PeriodontitisBiomarkersHumansPilot ProjectsPoint-of-Care TestingBiomarkersMatrix Metalloproteinase 8aMMP-8InfectionMetalloproteinaseOral and maxillofacial surgeryPilot study

Identifiers

PMID37249720
PMCPMC10776480
OpenAlexW4378745168

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.